Committees

Steering Committee: governs all activities of the PCR, including that of the Management Committee.

Management Committee: monitors day-to-day activities of the PCR and scopes reesarch projects for discussion by the Steering Committee.

Working Groups: work on specific prostate-related areas e.g. a brachytherapy group, general health and disease-specific quality of life group.



Members of the Steering Committee

Associate Professor Jeremy Millar (Chair)

A/Prof Jeremy Millar was the immediate past Director of the Southern Melbourne Integrated Cancer Service (SMICS) and is currently Director of Radiation Oncology at Alfred Health in Melbourne. In addition to a busy clinical practice looking after patients there, he oversees both an academic radiation centre in metropolitan Melbourne, as well as Alfred Health's satellite regional centre in Gippsland.  He leads the Radiation Oncology Genito-Urinary cancer group at Alfred Health and, as part of this, developed and leads a large prostate brachytherapy program, as well as an External Beam Radiotherapy Service. He is an adjunct Associate Professor at Monash University and his research and academic interests are are mainly in prostate cancer. Jeremy has worked in leadership roles in a number of other capacities relating to prostate cancer care, such as the Chairman of the Australasian Brachytherapy Group, Chair of the Genito-urological cancer committee of Victorian Co-operative Oncology Group , and from 2011 the chair of the VCOG executive committee.

Associate Professor Jeremy Millar

 

 

Professor Damien Bolton

 

Professor Bolton is Director of Urology at Austin Health and Professor of Surgery, University of Melbourne.  He is the current Chair of the Victorian Urologic Oncology Group of the Cancer Council. He has fifteen years post Fellowship of the Australasian College of Surgeons experience and is a member of multiple national and international learned societies, collaborative research groups, state and national committees, and national and international advisory boards. He is an elected member of the federal executive Urological Society of Australasia.  Professor Bolton has a busy academic urologic practice, with particular interest in urologic oncology. He has a leadership role in urologic cancer research, research training of urologic registrars, and national and regional reference service for minimally invasive treatment of urological cancers. He has a key role in supervision of clinical research and in education and training in Austin Health Cancer Services.

 

 


 

 

Associate Professor Ian Davis

 

A/Prof Ian Davis is a medical oncologist working at Austin Health and the Ludwig Institute for Cancer Research (LICR) in Melbourne, Australia, where he is Head of the Uro-Oncology Laboratory. He holds a Victorian Cancer Agency Clinical Researcher Fellowship and is an NHMRC Honorary Practitioner Fellow. His primary clinical interests are in urologic cancer and in melanoma, and his primary research interests are in cancer immunology and the biology of urologic cancers. A/Prof Davis is a member of the Cancer Council Victoria Urology and Skin Committees and the Standing Subcommittee on Research. He established and chairs the COSA Urologic Oncology Group and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Ltd (ANZUP).

Associate Professor  Ian Davis

 

 

Associate Professor Sue Evans

 

A/Prof Evans is a leading Investigator on a research program within the School of Public Health and Preventive Medicine, Monash University focusing on developing clinical registry science. She is a senior research fellow within the Centre of Research Excellence in Patient Safety and a National Health and Medical Research Council (NHMRC) Postdoctoral Public Health Fellow. A/Prof Evans is Vice President of the Victorian Healthcare Quality Association and Editor of the Australian Patient Safety Bulletin. She is Coordinator and of the Master of Health Services Management Principles of Quality Improvement in Healthcare Unit and a senior lecturer within Monash University. A/Prof Evans completed a PhD (Department of Medicine, University of Adelaide) investigating barriers to reporting of error by medical and nursing staff. She instituted a number of strategies to improve reporting, including a 24 hour call centre, which was the first of its kind in Australia. A/Prof Evans is the database custodian of the prostate cancer registry.

Dr Sue Evans

 

 

Professor Albert Frauman

 

Professor Frauman is the Chair of Clinical Pharmacology & Therapeutics at the University of Melbourne.  His major research activities involve drug discovery based on the use of biomarkers for prostate cancer metastasis as therapeutic and diagnostic targets.  He is also Medical Director of the Austin Centre for Clinical Studies, a 16 bed phase I clinical trials unit.  This integrated activity in drug discovery and development will allow for more efficient use of screening and testing of potential lead compounds for treatment of prostate cancer.  In addition Professor Frauman has significant undergraduate and postgraduate teaching and training activities and is involved in quality use of medicines activities at hospital and national levels.

Professor Albert Frauman

 

 

Associate Professor Mark Frydenberg

 

Associate Professor Mark Frydenberg graduated from the University of Melbourne, School of Medicine in 1982 with a MBBS (Hons) and was awarded FRACS in Urology in 1990. He then completed a formal urologic oncology fellowship specialising in prostate cancer management at the Mayo Clinic, USA. He works as a Urologist and Uro-oncologist within the multidisciplinary urology group Australian Urology Associates, as well as at Monash Medical Centre. He is currently the chairman of the Department of Urology at Monash Medical Centre and obtained a clinical associate professorship in the Monash University Departments of Surgery in 1997, and is Clinical Director of the Centre of Urological Research, Monash Institute of Medical Research.  Associate Professor Mark Frydenberg is also chairman of the Urological Oncology Special Advisory Group of the Urological Society of Australia and New Zealand. He is a board member of Andrology Australia, and the uro-oncology representative on the Education Sub-committee of the Prostate Cancer Foundation of Australia. He is an editorial board member of the BJU International as well as the Brazilian Journal of Urology, and reviews for these journals as well as Urology, Journal of Urology, Urologic Oncology, Medical Journal of Australia and ANZ Journal of Surgery.

Associate Professor Mark Frydenberg

 

 

Professor Graham Giles

 

Graham joined Cancer Council Victoria in 1983 as Director of the Victorian Cancer Registry. In 1986, he was appointed as Director of the Cancer Epidemiology Centre. He has honorary professorial appointments at Melbourne, Monash and Deakin Universities, and has served on several national and international committees including the Scientific Council of the International Agency for Research on Cancer in Lyons, France. He has published over 500 peer-reviewed papers and numerous reports. His H-index is 51.

His research interests have focused on the causes of cancers of the breast, prostate, bowel and skin; focusing on the roles of dietary factors and family history and genetics.  He is the chief investigator of the Melbourne Collaborative Cohort Study (Health 2000). He is also a principal investigator of a number of large population-based studies of families with cancers of the breast, bowel and prostate, and melanoma that he instigated in collaboration with Professor John Hopper at The University of Melbourne. Recently his interest has turned to the epidemiology of some of the less common cancers, including leukaemia and lymphoma. He has strong international collaborations especially in regard to prostate cancer genetics.

 

Professor Graham Giles

 

 

Professor John McNeil

 

John McNeil has been the head of the Monash University School of PublicHealth and Preventive Medicine based at the Alfred Hospital in Prahran since 1986. His research background is in epidemiology & clinical pharmacology.  He is currently a member of the Boards of the Colonial Foundation, the International Society of Cardiovascular Pharmacotherapy and Austin Health, Melbourne . He is a previous member of the Boards of Alfred Health, the Metropolitan Ambulance Service, Water Quality Research Australia and the Victorian Public Health Research and Education Foundation. He has been a member of ministerial committees reporting on renal failure services, organ transplantation and medical staff salaries. He also serves on scientific committees for the Red Cross Blood Transfusion Service, the National Blood Authority, the Therapeutics Goods Administration and the Australian Commission for Safety & Quality in Healthcare.  He is a member of the executive of the Monash Faculty of Medicine, Nursing & Health Sciences.  He has served on the senior medical staff of the Austin & Alfred Hospitals and the Monash Medical Centre.  In 2008 he was awarded an AM (Member of the Order of Australia) for services to Public Health.

 

Professor John McNeil

 

 

Associate Professor Declan Murphy

 

Declan Murphy moved to Melbourne, Australia in January 2010 to take up appointments as consultant urological surgeon at the Peter MacCallum Cancer Centre and the Royal Melbourne Hospital, and Director of Outcomes Research and Risk Stratification at the Australian Prostate Cancer Research Centre at Epworth Richmond. He had previously been consultant urological surgeon at Guys & St Thomas’ NHS Foundation Trust in London.  His main interests are laparoscopic and robotic-assisted cancer surgery and he is Director of Robotic Surgery at Peter Mac. He has published extensively in the field of minimally-invasive urology and is on the editorial board of the Journal of Robotic Surgery and is a reviewer for European Urology, The Journal of Urology, the BJU International and the Journal of Sexual Medicine. Declan is honorary clinical Associate Professor at the University of Melbourne and co-director of the Fellowship programme at Royal Melbourne and the Peter MacCallum Cancer Centre.

Associate Professor Declan Murphy

 

 

Mr Max Shub

 

Max Shub is a survivor of Advanced Prostate Cancer. Following his cancer diagnosis, he joined Prostate Heidelberg in 2005. Since then, he has had a number of roles in the support group network at state and national levels As a cancer survivor he is passionate about supporting other people who are making the cancer journey, ensuring that their special needs are met, and that they receive the optimum treatment for their particular condition.

Max Shub